EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023

Feb 13, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-02-09

Reporting Person: Lurker Nancy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-09	Common Stock	M	17533.00	$0.00	Acquired	170559.00	Direct
2023-02-09	Common Stock	M	20000.00	$0.00	Acquired	190559.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-09	Restricted Stock Units	$0.00	M	20000.00	Disposed		Common Stock (20000.00)	Direct
2023-02-09	Restricted Stock Units	$0.00	M	17533.00	Disposed		Common Stock (17533.00)	Direct

Footnotes

F1: Includes 2,745 shares acquired on January 31, 2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

F2: The restricted stock units vest in three annual installments beginning February 9, 2023.

F3: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.